key: cord-0798716-mcgpm9ll
authors: Ko, Jae-Hoon; Joo, Eun-Jeong; Kim, Sung-Han; Kim, Yae-Jean; Huh, Kyungmin; Cho, Sun Young; Kang, Cheol-In; Chung, Doo Ryeon; Kang, Eun-Suk; Peck, Kyong Ran
title: Clinical Application of Rapid Diagnostic Test Kit for SARS-CoV-2 Antibodies into the Field of Patient Care
date: 2020-07-10
journal: J Microbiol Immunol Infect
DOI: 10.1016/j.jmii.2020.07.003
sha: 342d2f0a3af687c35fb24acbafbd40d05411ce9f
doc_id: 798716
cord_uid: mcgpm9ll

Abstract Clinical applicability of rapid diagnostic test kit for SARS-CoV-2 antibodies was evaluated. The kit detected antibodies from day 9 to 56 of illness. IgG bands were observed up to 1: 1,000 dilutions. The kit could detect 90.5% of IgG and 61.9% of IgM antibodies of mild febrile patients without pneumonia.

Clinical applicability of rapid diagnostic test kit for SARS-CoV-2 antibodies was evaluated. The kit 2 detected antibodies from day 9 to 56 of illness. IgG bands were observed up to 1: 1,000 dilutions. The Global spread of coronavirus disease 2019 outbreak is rapidly progressive. 1 Although 2 detection of viral RNA by reverse transcription-polymerase chain reaction (RT-PCR) is the standard 3 for the diagnosis of COVID-19, 2 need for serologic test is increasing for an alternative diagnostic 4 method and/or seroprevalence studies. Rapid diagnostic test (RDT) kits for severe acute respiratory 5 syndrome coronavirus 2 (SARS-CoV-2) antibodies are easy to use and require 15 minutes for the test. 6 To date, many RDT kits detecting SARS-CoV-2 IgM and/or IgG antibodies have been developed, but 7 validation data with various clinical aspects are limited. 3, 4 For clinical application of RDT kits in the 8 field of COVID-19 management, we evaluated performance according to the day of illness, type of 9 specimens, feasibility as a point-of-care test (POCT), severity of illness, and with ten-fold titrations.

We performed SARS-CoV-2 IgM and IgG antibody tests using a RDT kit that had been used in recent 12 report, 4 in eight pneumonic COVID-19 patients and 21 mild febrile COVID-19 patients without 13 pneumonia. SARS-CoV-2 infections of the evaluated patients were confirmed by RT-PCR. Pneumonic 14 patients were admitted at tertiary care hospitals. Pneumonia was documented by chest X-ray and/or 15 computed tomography. Onset of illness and clinical course were clearly documented. Day of illness 16 was counted from the symptom onset (symptom onset day as D1), and the first week of illness 17 denoted illness days from D1 to D7. Mild patients were cared at a life treatment center (LTC), 5 18 meeting all of the following conditions: 1) mentally alert, 2) body-temperature below 37.5°C at 19 admission, 3) under 60 year of age, 4) no underlying disease, 5) non-smoker, and 6) no radiologic 20 evidence of pneumonia. Among these mild patients, patients who experienced febrile sense, chilling, 21 and/or myalgia were selected. Written informed consents were obtained from the patients. This study 22 was approved by the Institutional Review Boards of the Samsung Medical Center (IRB No. 2020-03-23 113 and 2020-03-120).

The RDT kits using lateral flow immunoassay principle were assembled at Korea (Wells Bio Inc.,

Seoul, Korea) using the materials manufactured by Jiangsu Medomics Medical Technology (Nanjing, China). 4 It is able to detect both IgM and IgG separately, targeting SARS-CoV-2 spike protein and 1 supposed to use serum, plasma, and whole blood (WB) specimen and the manufacturer reported 2 sensitivity of the kit was 88.66% and specificity was 90.63%. Test was performed according to the 3 manufacturer's instructions. 4 Interpretation of the test results is described in the supplementary 4 material in detail.

In overall, 52 specimens from 21 mild febrile and 8 pneumonic COVID-19 patients were evaluated 7 (Supplementary Table 1 ). Among 43 specimens collected after the second week of illness (after D14), To assess the feasibility of RDT kit as a POCT, we tested three WB specimens at the bed-side of 18 patients ( Figure 1 -(a)). WB from arterial (taken from arterial line) and venous blood (taken from 19 routine peripheral blood sampling) showed strong bands on IgG bands within two minutes after 20 dropping two to three drops of blood on the test wells without adding additional dilution buffers, 21 which were different from manufacturer's instruction as applying 15 µL WB and two to three drops of 

For the evaluation of test performance according to the types of blood specimens, we compared 26 WB, plasma, and serum specimens taken at the same day from patient 3 (Supplementary Figure 2-(a) ).

The intensity of IgG band was slightly stronger while IgM band was fainter with WB specimen, 2 compared to plasma and serum specimens. Results using plasma and serum specimens did not show 3 noticeable differences. This difference was also noted with the samples from Patient 4, taken by four-4 day interval (Supplementary Figure 2-(b) ).

To see performance according to the day of illness, we tested serial serum specimens collected from on D9 with weak intensities for pneumonic patient. IgG bands became more intense with following 9 specimens. As we did not collect specimen between D5 and D9, whether the kit could detect IgM 10 earlier than IgG was not be evaluated for this pneumonic patient. Meanwhile, for Patient 29, the RDT 11 kit could detect earlier response of IgM on D11. IgG band was noticed on D18 specimen for this mild 12 febrile patient. 14 To evaluate feasibility for seroprevalence study, convalescent sera from 21 mild febrile COVID-19 15 patients without pneumonia were evaluated (Figure 1-(c) ). Eight patients (38.1%) were male and the 16 mean age was 32.2 years old. The sampling day ranged from D18 to D56. Nineteen specimens (90.5%) 17 were positive for IgG bands, including four weakly positive (Patient 10, 14, 20, and 29) and two very 13, 14, 19, 22, 24, and 28). One specimen was negative for both IgG and IgM, and overall intensity of 21 bands was weaker than specimens from pneumonic patients. 23 Feasibility of RDT kit as a semi-quantitative method was also evaluated with ten-fold titrations.

Convalescent sera collected from two pneumonic patients (Patient 3 and 4) and five mild febrile 25 patients (Patient 11, 13, 17, 27, and 28) were diluted with PBS buffer from 1:10 to 1:100,000 ( Figure  1-(d) ). Sera from two pneumonic patients showed positive IgG intensity by 1:100 dilutions, and the 1 bands became weakly positive at 1:1,000 dilutions. Meanwhile, among five mild febrile patients, none 2 of specimens showed positive IgG intensity at 1:100 dilutions (compared to pneumonic patients by 3 the Chi-square test, P = 0.048); four showed weakly positive intensity and one was negative.

Based on the initial performance data of serologic test kits for emerging diseases, 3 clinical feasibility 6 should be evaluated according to the purpose of serologic test. For the diagnostic purpose, we noticed 7 the kit can detect IgG and IgM antibodies from D9 of illness. A published serologic study using 8 enzyme linked immunosorbent assay (ELISA) suggested that the median time of seroconversion was 9 D12 for IgM and D14 for IgG. 6 Another report also presented presence of IgM and IgG antibodies 10 from the 3 rd week of illness. 7 In the present test, it was noticed that the RDT kit detected IgG 11 antibodies in 95.3% of specimens collected after the second week of illness (after D14), suggesting 12 that the performance of the kit would be comparable to previous reports.

Of note, we also tested feasibility of RDT kit as a semi-quantitative method with ten-fold dilution 14 of serum specimen, and noticed that RDT kit could detect IgG antibodies of 1:1,000 diluted sera. As 15 of the current COVID-19 pandemic, convalescent plasma infusion therapy is one of potential 16 treatment options for severe 9 For the selection of donor plasma, measurement of 17 functional anti-SARS-CoV-2 antibodies by neutralization test is necessary. However, facilities for 18 neutralization tests are not readily available, non-culture based methods can be used for titrations of 19 antibodies 10 . Our finding provided that RDT kit can be used for a semi-quantitative method for 20 assessing amount antibodies, which would be useful in resource limited settings.

Lastly, performance of detecting antibodies in convalescent serum of mild illness was evaluated.

The main purpose of seroprevalence study in the current pandemic would be to detect potential 23 undiagnosed COVID-19 patients, who are likely to be mild cases. As antibody response in mild illness 24 would be weak, whether an antibody test kit can detect serologic response in these patients is an 

Korean Society of Infectious Diseases KSoPID

Control and Prevention and Korea Centers for Disease Control and Prevention

Guidelines for Laboratory Diagnosis 7 of Coronavirus Disease 2019 (COVID-19) in Korea

Development and Clinical Application of A 9

Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis

Immunoassay and Colloidal Gold-Immunochromatographic Assay Kit for Detection of 13

Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia

Early diagnosis and rapid isolation: response to COVID-19 outbreak in Korea

Microbiol Infect

Antibody responses to SARS-CoV-2 in 18 patients of novel coronavirus disease 2019

Profile of Specific Antibodies to SARS-CoV-2: The First 20

Use of Convalescent Plasma 22